INDUSTRY NEWS
'Beyond Weight Management: The Hidden Complications of Canine Obesity' typography against a background featuring a large white dog sitting on a scale
By Stephanie Loter, DVM
O

besity affects well over a third of dogs in North America, and its prevalence continues to climb annually.1 Pet owner awareness of the body condition of their pets is also growing with 35% of dog owners in 2024 categorizing their pet as being overweight or obese, doubling from the pet owner awareness reported in 2023.1

Conversely, only 27% of dog owners recall having their veterinarian provide them with a distinct body condition score for their dog.1 Some veterinary professionals acknowledge hesitation due to perceived owner discomfort about pet obesity discussions, though. In one survey, 69% of pet owners reported they did not feel uncomfortable with being told their pet needed to lose weight.1 These findings reiterate the importance of veterinary professionals to continue to have conversations about weight management in their patients.

For the modern veterinary professional, weight management must go far beyond simple calorie restriction. Obesity is now recognized as a systemic, chronic inflammatory disease that impacts all major organ systems—often before overt clinical signs become apparent. The veterinary role now involves not just addressing excess weight, but also identifying and managing the hidden, potentially irreversible complications that often develop in overweight and obese dogs.

The Health Storm Behind Obesity
Canine obesity triggers a cascade of changes throughout the body. Hidden metabolic changes may quietly progress for years, contributing to insulin resistance and predisposing to diabetes. Cardiovascular and respiratory systems face increased workload and fat infiltration, while joints—already under excessive mechanical stress—undergo accelerated degeneration. Chronic inflammation and altered adipokine signaling raise risks for cancer, skin problems and immune dysfunction. Tragically, obesity can reduce a dog’s lifespan by up to two-and-a-half years, often with a significant decline in daily quality of life.2
Case Example: Charlie, a Nine-Year-Old Labrador Retriever with OA
Charlie, a neutered male Labrador weighing 42 kg with a BCS 8/9 (ideal: 32 kg), presented for a semiannual visit. His owner reported “slowing down,” occasional hopping on walks and having difficulty rising. On examination, Charlie’s hips and elbows were stiff, with reduced range of motion and palpable crepitus. His stifle was stable but mildly thickened. Blood work showed mildly increased triglycerides. Charlie’s owner believed he was “just getting older,” unaware that even moderate weight gain could directly worsen joint pain and overall health.

A focused OA assessment confirmed mild-to-moderate pain with decreased activity at home. The team initiated a structured weight-loss plan, switching Charlie to a prescription, high-protein/fiber, calorie-controlled diet with strict treat limits. NSAID therapy was started, and a rehabilitation consult was arranged for a tailored exercise regimen. After three months, Charlie’s weight had decreased by 2 kg, BCS improved and activity scores markedly increased. His owner noted greater playfulness, better mobility and a return to favorite activities.

This example highlights both the common denial of obesity’s impact and how a multimodal approach can reverse an accelerating cycle of pain and disability.3

Metabolic, Cardiovascular and Orthopedic Complications: A Closer Look
Obese dogs frequently develop “silent” metabolic dysfunction, with chronic low-grade inflammation leading to insulin resistance, hyperlipidemia and increased risk of pancreatitis—even before clinical diabetes. Cardiovascular risks include early hypertension, cardiac remodeling and reduced exercise tolerance. Orthopedic acceleration is perhaps the most visible: Joint overloading and decreased movement as well as accelerated OA progression can be seen in obese dogs, both young and old.
Metabolic Dysfunction

Obesity in dogs is fundamentally a metabolic disease, driven by chronic overnutrition and reduced physical activity. Excess adipose tissue is not inert—it’s hormonally active, secreting pro-inflammatory cytokines (e.g., TNF-α, IL-6) and adipokines (e.g., leptin, resistin) that trigger a state of chronic low-grade inflammation. This systemic inflammation underlies many of the early, hidden complications of obesity. Key metabolic consequences include:

  • Insulin Resistance/Prediabetes: Obese dogs show reduced sensitivity to insulin, as evidenced by impaired glucose tolerance. Persistent insulin resistance increases the risk for overt diabetes mellitus (especially in breeds like Miniature Schnauzers, Dachshunds and Poodles).4,5
  • Dyslipidemia: Elevated triglyceride and cholesterol levels are frequently found in overweight dogs. This not only increases the risk of pancreatitis, but also accelerates the development of atherosclerotic changes in blood vessels—though true atherosclerosis is less common in dogs compared to humans.6
  • Metabolic Syndrome: A cluster of abnormalities—including abdominal obesity, hypertension, dyslipidemia and impaired fasting glucose—may be present even in preclinical obese dogs, mirroring human metabolic syndrome.
  • Pancreatitis & Hepatic Lipidosis: Hyperlipidemia in obese dogs predisposes to pancreatitis, a potentially life-threatening complication. Hepatic lipidosis (fatty liver) and mild elevations in liver enzymes can be detected in overweight patients, even before clinical signs emerge.7
  • Chronic Low-Grade Inflammation: Adipose-derived cytokines maintain oxidative stress and endothelial dysfunction, further driving metabolic derangement.

A clinical approach should include annual or more frequent metabolic screening (fasted glucose, lipids, ALT/ALP) for any dog with BCS >7/9 or rapid weight gain. And in overweight patients, even mild “out-of-range” results should prompt early intervention and close monitoring.

Cardiovascular and Respiratory Complications

Obesity imposes significant hemodynamic and respiratory burden—even without clinical “heart disease” or apparent respiratory distress. Major cardiovascular risks include:

  • Increased Cardiac Workload: Excess body fat increases blood volume and cardiac output requirements, leading to ventricular remodeling and, over time, possible cardiac insufficiency.
  • Systemic Hypertension: Obese dogs are at higher risk for hypertension, which predisposes to target-organ damage (kidney, eyes, heart, brain).8
  • Arrhythmias: Although less common, abnormal fat deposition around the heart may disrupt normal conduction, occasionally increasing arrhythmogenic risk in severely obese dogs.

Respiratory complications include:

  • Decreased Pulmonary Compliance: Fat accumulation in the thorax and abdominal cavity restricts diaphragmatic motion, reducing tidal volume and vital capacity.
  • Exacerbation of Brachycephalic Obstructive Airway Syndrome (BOAS): Even slight weight gain in brachycephalic breeds can convert a subclinical case to a significant one, resulting in distress or crisis, especially under anesthesia.
  • Increased Anesthetic Risk: Studies show that obese dogs have delayed recovery and greater risk of perioperative hypoxia, aspiration and post-anesthetic complications.9,10

A clinical approach should include routine blood pressure screening in obese or at-risk patients (age >7 years, BCS ≥6/9 or breeds predisposed to hypertension). Baseline thoracic auscultation, and in some cases imaging, for panting, “exercise intolerance” or “nothing more than old age” complaints should be considered. In addition, pre-anesthetic evaluation should assume increased respiratory and cardiac risk, necessitating conservative sedation protocols and vigilant monitoring.

Orthopedic Acceleration and Chronic Pain
Musculoskeletal disease is a hallmark complication of canine obesity, resulting in both acute injuries and the insidious progression of chronic pain. Key points include:

  • Early-Onset Osteoarthritis (OA): Overweight dogs develop OA at a younger age and with more severe radiographic and clinical changes. Weight-induced mechanical overload and the inflammatory cytokine environment promote cartilage degeneration, synovitis and pain.3
  • Ligamentous Injuries: Obesity is a strong risk factor for cranial cruciate ligament rupture and patellar luxation.11,12 Surgical outcomes are often poorer in overweight dogs, with longer recovery times and more complications.13
  • Reduced Mobility & Sarcopenia: Obese dogs are less willing or able to exercise, which rapidly leads to muscle wasting (“sarcopenia”) and further exacerbates joint instability and pain. This can become a vicious cycle—weight restricts movement, which increases fat and deteriorates muscle and joint health.
  • Pain Masking: Owners often attribute reduced activity, reluctance to climb stairs or difficulty rising to “normal aging,” failing to recognize that these are cardinal signs of OA pain exacerbated by excess weight. Clinical pain scoring systems, such as LOAD or CBPI, are valuable for monitoring.

A clinical approach should include performing thorough orthopedic and neurologic examinations in any overweight or obese dog at every annual and sick-patient visit—even subtle gait changes may represent significant pain. Early, multimodal OA therapy (NSAID, weight loss, joint diets, rehabilitation) should be initiated at the first sign of pain or joint swelling. Even weight loss as modest as 6% can significantly reduce lameness and increase mobility.14

Diagnostic Protocols for Hidden Complications
Early identification of secondary disease is vital. This begins with universal BCS scoring (1–9 scale) at every visit, annual documentation of “healthy” adult weight, and in-depth questioning about subtle activity, attitude and appetite changes. Dogs with BCS ≥8/9, unexplained weight gain or “slowing down” should receive routine metabolic, lipid and orthopedic/neurologic screenings. Lab panels may include glucose, cholesterol, thyroid function tests, and liver and kidney enzymes; advanced tests and imaging can be employed as clinical suspicion dictates.
Comprehensive Management Strategies
Weight loss and complication control demand a coordinated, multimodal approach, which includes the following:

  1. Nutritional Therapy: Prescription hypocaloric diets high in protein and fiber, and strict treat control are paramount. Omega-3 (EPA/DHA) supplementation is recommended for anti-inflammatory and metabolic support, targeting a minimum daily dose of 100 mg/kg EPA/DHA.3
  2. Pain Management/OA Therapy: Early, sustained NSAIDs are cornerstones for obese dogs with OA. Experts in orthopedic disease recommend starting with one to three months of daily NSAID therapy at initial OA diagnosis before considering tapering, with moderate to severe cases often requiring life-long daily treatment.3
  3. Physical Rehabilitation: Tailored exercise plans can help restore function and aid safe activity, minimizing injury risk as weight is reduced.
  4. Routine Monitoring: Rechecks should be performed every two to four weeks initially, with adjustment based on weight, BCS, labs and response to therapy.
Case Example: Daisy, the Active Senior with Subtle Cardiac Compromise
Daisy, an 11-year-old Beagle, appeared normal except for a BCS of 7/9 at her wellness visit. The owner denied limping but noted that Daisy “panted more on walks.” Her blood pressure reading was at the upper end of normal, and a screening metabolic panel revealed mild hyperlipidemia.

Daisy’s plan included a calorie-restricted diet, increased walk frequency, and regular monitoring of blood pressure and cardiac function. When rechecked four months later, Daisy had lost 1.5 kg, her blood pressure had normalized and her stamina had improved. Early cardiovascular screening and intervention prevented progression to more serious disease.

Effective Client Communication
Veterinarians must communicate the serious, multisystem impact of obesity directly and compassionately. Explain risks (“Obesity is not just extra weight—it causes internal disease and pain”), use owner-friendly BCS visuals and reinforce that the clinic is a partner, not a judge.

Encourage owners to track treats and activity using journals or apps, celebrate small wins and tailor follow-up to reinforce momentum. Proactive, nonjudgmental and consistent messaging is essential for long-term success.

Clinic Implementation
Internally, BCS, weight, and comorbidity checklists should be incorporated into every annual and interim exam. Use EMR prompts and team checklists to monitor and follow progress. In addition, clinics should design “obesity complication” flags and provide regular staff training, ensuring the whole team is engaged in prevention and management.

Obesity is a serious medical disease that demands immediate, coordinated and comprehensive intervention. By recognizing and treating its hidden complications—metabolic, cardiovascular and orthopedic—alongside sustained weight management, veterinary teams can truly improve both the quality and length of their patients’ lives.

References:
  1. 2024 Pet Obesity and Nutrition Survey Highlights. (2025). Association for Pet Obesity Prevention. https://www.petobesityprevention.org/2024-survey
  2. Kealy, R., Lawler, D., Ballam, J., et al. (2002). Effects of diet restriction on life span and age-related changes in dogs. Journal of the American Veterinary Medical Association, 220(9), 1315-1320. https://doi.org/10.2460/javma.2002.220.1315
  3. Cachon, T., Frykman, O., Innes J., et al. (2023). COAST Development Group’s international consensus guidelines for the treatment of canine osteoarthritis. Front Vet Sci. 10:1-23. https://doi.org/10.3389/fvets.2023.1137888
  4. Qu, W., Chen, Z., Hu, X., et al. (2022). Profound perturbation in the metabolome of a canine obesity and metabolic disorder model. Front Endocrinol. 13:1-16. https://doi.org/10.3389/fendo.2022.849060
  5. Behrend, E., Holford, A., Lathan, P., et al. (2018). 2018 AAHA Diabetes Management Guidelines for Dogs and Cats. J Am Anim Hosp Assoc. 54:1-19. https://www.aaha.org/wp-content/uploads/globalassets/02-guidelines/diabetes/2018-aaha-diabetes-management-guidelines-2022-update.pdf
  6. Söder, J. (2018). Metabolic variations in canine overweight: Aspects of lipid metabolism in spontaneously overweight Labrador Retriever dogs. Acta Universitatis Agriculturae Sueciae. 62. https://pub.epsilon.slu.se/id/document/16584183
  7. Belotta, A., Teixeira, C., Padovani, C., et al. (2017). Sonographic Evaluation of Liver Hemodynamic Indices in Overweight and Obese Dogs. JVIM. 32(1):181-187. https://onlinelibrary.wiley.com/doi/full/10.1111/jvim.14883
  8. Gomes, C., Morais, C., Lima, S., et al. (2025). Canine Obesity: Contributing Factors and Body Condition Evaluation. Pets, 2(2), 22. https://doi.org/10.3390/pets2020022
  9. Love, L., Cline, M. (2015). Perioperative physiology and pharmacology in the obese small animal patient. Vet Anaesthesia Analgesia. 42:119-132. https://doi.org/10.1111/vaa.12219
  10. Redondo, J., Otero P., Martinez-Taboada F., et al. (2023). Anesthetic mortality in dogs: A worldwide analysis and risk assessment. Vet Record. 195(1):e3604. https://doi.org/10.1002/vetr.3604
  11. Adams, P., Bolus R., Middleton, S., et al. (2011). Influence of signalment on developing cranial cruciate rupture in dogs in the UK. J Small Anim Prac. 52(7):347-352. https://doi.org/10.1111/j.1748-5827.2011.01073.x
  12. Andrade, M., Slunsky, P., Klass, L., Brunnberg, L. (2020). Risk factors and long-term surgical outcome of patellar luxation and concomitant cranial cruciate ligament rupture in small breed dogs. Veterinarni Medicina. 65(4):159-167. https://vetmed.agriculturejournals.cz/pdfs/vet/2020/04/02.pdf
  13. Fitzpatrick, N., Solano, M. (2010). Predictive variables for complications after TPLO with stifle inspection by arthrotomy in 1000 consecutive dogs. Vet Surg. 39:460-474. https://doi.org/10.1111/j.1532-950X.2010.00663.x
  14. Marshall, W., Hazewinkel, H., Mullen, D., et al. (2010). The effect of weight loss on lameness in obese dogs with osteoarthritis. Vet Res Commun. 34(3):241-253. https://doi.org/10.1007/s11259-010-9348-7
Dr. Loter headshot
Dr. Loter has clinical experience in equine, bovine & small ruminant, and small animal medicine and is an in-house veterinarian for Elanco Animal Health. Dr. Loter is passionate about promoting Fear Free handling techniques and supporting veterinary mental health as a Fear Free Certified Professional and a Mental Health First Aider. Dr. Loter supports the Elanco team and customers with technical expertise on a variety of Elanco treatments and promotion of product development opportunities in the small animal medicine space.
Back to Issue